# South America Biosimilar Contract Manufacturing Market > South America Biosimilar Contract Manufacturing Market Research Report By Product (Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins), By Production Technology (Mammalian, Non-Mammalian), By Application (Oncology, Blood Disorders, Growth Hormonal Deficiency, Chronic & Autoimmune Disorders, Rheumatoid Arthritis, Others) and By Regional (Brazil, Mexico, Argentina, Rest of South America) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 3.35% - **2024:** $ 386.43 Million - **2025:** $ 373.48 Million - **2035:** $ 265.61 Million - **Key Players:** Samsung Biologics (KR), Lonza Group (CH), Boehringer Ingelheim (DE), Fujifilm Diosynth Biotechnologies (JP), Catalent (US), Wuxi Biologics (CN), Rentschler Biopharma (DE), KBI Biopharma (US), Amgen (US) **Report ID:** MRFR/Pharma/50114-HCR · **Pages:** 200 · **Author:** Nidhi Mandole & Garvit Vyas · **Last Updated:** February 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/south-america-biosimilar-contract-manufacturing-market-51872 --- ## Market Summary ## **South America Biosimilar Contract Manufacturing Market Overview** As per MRFR analysis, the South America Biosimilar Contract Manufacturing Market Size was estimated at 520.1 (USD Million) in 2023. The South America Biosimilar Contract Manufacturing Market Industry is expected to grow from 618.4(USD Million) in 2024 to 4,151.99 (USD Million) by 2035. The South America Biosimilar Contract Manufacturing Market CAGR (growth rate) is expected to be around 18.9% during the forecast period (2025 - 2035). ### **Key South America Biosimilar Contract Manufacturing Market Trends Highlighted** The South American Biosimilar Contract Manufacturing Market is undergoing substantial growth as a result of a variety of market drivers that are influencing the landscape. The increasing prevalence of chronic diseases in the region is a significant market driver. The demand for affordable and effective biologics is on the rise as healthcare systems endeavor to effectively manage these conditions. Biosimilars are capable of meeting this demand. In addition, the development and production of biosimilars are being promoted by government initiatives in countries such as Argentina and Brazil to guarantee patient access and develop domestic healthcare solutions. This has resulted in increased investments in contract manufacturing infrastructures and biotechnology in South America. Collaborations between international biotechnology firms and local manufacturers are among the opportunities to be investigated in this market. These partnerships can expedite the market entry of biosimilars and improve production capabilities by capitalizing on local expertise. In addition, the robust regulatory framework being established by agencies such as ANVISA in Brazil is fostering opportunities for increased consumer confidence in biosimilars, which will result in a greater adoption. There has been a recent trend in South America towards a more supportive policy environment for biosimilars. Biosimilars are emerging as an appealing alternative to original biologics amid the growing emphasis on healthcare cost reduction. Additionally, there is an increasing commitment to sustainability and local manufacturing, which is consistent with the broader global trend of minimising the carbon footprint of medical supplies. These factors are collectively influencing the South America Biosimilar Contract Manufacturing Market, as stakeholders adjust to the region's changing healthcare needs. The future is promising. Source: Primary Research, Secondary Research, _Market Research Future_ Database**,****and Analyst Review** ### **South America Biosimilar Contract Manufacturing Market Drivers** #### **Increasing Demand for Cost-effective Healthcare Solutions** The healthcare expenditure in South America is rising, with a significant push towards budget-friendly options, especially in countries like Brazil and Argentina. According to the Pan American Health Organization, more than 50% of the population in these countries faces high out-of-pocket costs for medications. This drives the demand for biosimilars, known for their affordability compared to originator biologics. The presence of established organizations like Biocon and Sandoz is further promoting this trend, as they are increasingly engaging in local partnerships to manufacture biosimilars. These companies are expected to lead the South America Biosimilar Contract Manufacturing Market by developing localized manufacturing strategies while addressing the high costs of biologics and improving access to effective treatments. #### **Rising Prevalence of Chronic Diseases** The prevalence of chronic diseases, such as diabetes and cancer, is a pivotal factor in driving the demand for biosimilars in South America. The World Health Organization reports that the incidence of diabetes in South America is expected to rise by over 30% by 2030, translating to millions of new patients requiring management with biologic treatments. This escalation will compel healthcare providers to explore biosimilars as viable treatment options. Furthermore, organizations like the Latin American Society of Medical Oncology (SLACOM) are advocating for greater use of biosimilars by educating both healthcare professionals and patients on their benefits, thereby significantly propelling the growth of the South America Biosimilar Contract Manufacturing Market. #### **Supportive Regulatory Environment** The South American region has seen an evolution in regulatory frameworks that favor the acceleration of biosimilar approval processes. Regulatory agencies such as ANVISA in Brazil have created clear guidelines for biosimilars, thus facilitating quicker market entry. Research shows that under the current regime, the average approval time for biosimilars could be cut down by 25%, significantly impacting market dynamics. The active pursuit of expanding biosimilar markets by local governments is showing promise for the South America Biosimilar Contract Manufacturing Market Industry. By streamlining the regulatory pathway, the authorities aim to encourage local manufacturing and investment in the sector, directly contributing to a more robust infrastructure for biosimilars. #### **Advancements in Biotechnology and Manufacturing Processes** Technological innovation in the biotechnology sector is revolutionizing the biosimilar landscape in South America. With substantial investments in biopharmaceutical R&D from established companies such as Roche and Pfizer, new manufacturing techniques are being developed that enhance efficiency and reduce costs. According to the Argentina Biopharmaceuticals Association, the number of biotech companies has increased by 20% over the last five years, driving the growth of advanced manufacturing capabilities. This progress equips the South America Biosimilar Contract Manufacturing Market with the necessary tools to produce high-quality biosimilars that can compete with leading biopharmaceutical firms globally, thus enhancing local healthcare offerings. ### **South America Biosimilar Contract Manufacturing Market Segment Insights** #### **Biosimilar Contract Manufacturing Market Product Insights** The South America Biosimilar Contract Manufacturing Market is increasingly diverse, with the product segment serving as a foundation for its expansion. A key focus within this segment is recombinant proteins, which have been instrumental in the development of biologic therapies. The market is predominantly influenced by two main categories recombinant non-glycosylated proteins and recombinant glycosylated proteins, each playing a distinct role in advancing therapeutic applications. Recombinant non-glycosylated proteins, known for their stability and cost-effectiveness, are commonly used in various therapeutic contexts, such as hormones and enzymes. They have seen demanding growth due to rising healthcare needs in the region. Conversely, recombinant glycosylated proteins, essential for mimicking complex human proteins, dominate due to their crucial role in developing monoclonal antibodies and other advanced therapies. The importance of these proteins lies in their ability to offer treatments that are often more effective and economically viable than their traditional counterparts, thus providing a solid foundation for innovation in the biosimilar space. The regulatory landscape in South America also reflects an increasing focus on biosimilars, which aligns with global trends towards cost-containment in healthcare, driving the demand for these products. As countries in the region invest in healthcare infrastructure and biotechnology, the biosimilar contract manufacturing market stands to benefit significantly, with both recombinant non-glycosylated and glycosylated proteins expected to play pivotal roles in transforming patient access to essential medicines. The growth in biopharmaceutical production capabilities, particularly in Brazil and Argentina, further supports this trend, fostering a robust ecosystem for biosimilar development. Thus, the segmentation of the South America Biosimilar Contract Manufacturing Market highlights the progressive fabric of the biopharmaceutical landscape, wherein protein-based therapies are set to lead the charge toward more sustainable, effective healthcare solutions across the region. Source: Primary Research, Secondary Research, _Market Research Future_ Database**,****and Analyst Review** #### **Biosimilar Contract Manufacturing Market Production Technology Insights** The Production Technology segment within the South America Biosimilar Contract Manufacturing Market has emerged as a critical pillar driving market dynamics. This sector is primarily divided into Mammalian and Non-Mammalian technologies, both playing pivotal roles in the development and manufacturing processes of biosimilars. Mammalian cell culture systems are often preferred due to their capability to produce complex proteins that closely mimic human biological characteristics, contributing significantly to the efficacy and acceptance of biosimilar products. Conversely, Non-Mammalian systems, including microbial fermentation, are gaining traction for their cost-effectiveness and rapid production cycles, catering to a diverse range of therapeutic applications. The growing need for efficient and scalable manufacturing processes, driven by increased demand for affordable biologics in South America, is propelling investments in both technologies. Additionally, regional regulatory frameworks are evolving to support the growth of biosimilars, fostering an environment that encourages innovation in production techniques. Overall, the balance between Mammalian and Non-Mammalian technologies exemplifies the efforts toward enhancing quality and reducing production costs in the ever-evolving landscape of the South America Biosimilar Contract Manufacturing Market. #### **Biosimilar Contract Manufacturing Market Application Insights** The South America Biosimilar Contract Manufacturing Market, specifically within the Application segment, encompasses various critical therapeutic areas, each playing a significant role in addressing diverse patient needs. Oncology has emerged as a pivotal focus area due to the increasing prevalence of cancer and the rising demand for effective treatment options, where biosimilars contribute to enhanced patient access and affordability. Blood Disorders also represent a substantial segment, with biosimilars assisting in the management of conditions like hemophilia, promoting cost-effective treatment strategies in healthcare systems across South America. Additionally, the segment addressing Growth Hormonal Deficiency has gained traction, as the region experiences a heightened awareness of growth-related disorders. Chronic and Autoimmune Disorders, including Rheumatoid Arthritis, signify another important area, driven by a growing aging population and an upsurge in autoimmune conditions. The diversity in these applications reflects the South America Biosimilar Contract Manufacturing Market dynamics, where strategic investments and collaborations are expected to drive innovations, improve patient outcomes, and adapt to evolving healthcare demands. Overall, these various applications highlight the ongoing trends and opportunities within the South America Biosimilar Contract Manufacturing Market, responding to pressing healthcare challenges and ensuring that patients have better access to biologic therapies. #### **Biosimilar Contract Manufacturing Market Regional Insights** The South America Biosimilar Contract Manufacturing Market is characterized by significant growth potential in its regional segmentation, comprising Brazil, Mexico, Argentina, and the Rest of South America. Brazil stands out as a leader in the market, driven by robust investments in healthcare infrastructure and a rising demand for cost-effective biologics, presenting ample opportunity for contract manufacturers. Mexico is emerging as a competitive market due to its strategic location and favorable regulatory environment, facilitating partnerships between domestic and international manufacturers. Argentina is gaining traction as a significant player, where local pharmaceutical companies are increasingly adopting biosimilars to enhance patient access to biologic therapies. The Rest of South America, including countries such as Chile and Colombia, is also contributing to the overall market dynamics through growing healthcare expenditure and a rising awareness of biosimilars. The entire region benefits from a combination of rising chronic disease prevalence and increasing healthcare costs, pushing stakeholders toward biosimilar solutions. This landscape allows for targeted strategies and innovative collaborations, making the South America Biosimilar Contract Manufacturing Market an attractive segment for investments and growth. #### **South America Biosimilar Contract Manufacturing Market Region** Source Primary Research, Secondary Research, MRFR Database, and Analyst Review ### **South America Biosimilar Contract Manufacturing Market Key Players and Competitive Insights** The South America Biosimilar Contract Manufacturing Market is gaining significant traction due to several factors, including increasing demand for affordable medicinal alternatives, growing investments in biopharmaceutical manufacturing, and favorable regulations promoting the use of biosimilars. With more companies seeking partnerships to leverage existing manufacturing capabilities, the competitive landscape in this market has become increasingly dynamic. Companies are focusing on establishing robust supply chains, investing in advanced technologies, and enhancing their manufacturing capabilities to meet the burgeoning demand for biosimilars across various therapeutic areas. This heightened competition is pushing organizations to develop strategic alliances and expand their product portfolios to effectively capture market share, thereby leading to innovative solutions that cater to the nuanced needs of healthcare providers and patients alike in South America. Biocon has established a prominent presence in the South America Biosimilar Contract Manufacturing Market, primarily focusing on delivering high-quality biosimilars at a competitive price point. The company's strengths lie in its extensive experience in biologics manufacturing, advanced research and development capabilities, and a commitment to quality assurance. Biocon has been instrumental in expanding the biosimilars market in the region through strategic collaborations and local partnerships that enhance its ability to navigate various regulatory environments. By prioritizing innovation and patient-centric approaches, Biocon has strengthened its foothold in South America, providing essential biopharmaceutical solutions that align with the growing demand for affordable healthcare. Sandoz, a leader in the biosimilars sector, has made significant strides within the South America Biosimilar Contract Manufacturing Market through a comprehensive portfolio of products that includes monoclonal antibodies and biologics targeting various chronic diseases. The company is recognized for its commitment to quality and cost-effective solutions that help improve patient accessibility to biopharmaceuticals. Sandoz's strengths lie in its strong global network, advanced manufacturing facilities, and a robust pipeline of sequential biosimilars, all of which bolster its influence in the South American market. Additionally, Sandoz has been active in forging mergers and acquisitions that enhance its operational capabilities and extend its product offerings, thereby ensuring a sustained competitive edge. This focus on innovation and strategic growth has positioned Sandoz favorably to meet the healthcare needs of South American patients while maintaining a strong presence in the industry. #### **Key Companies in the South America Biosimilar Contract Manufacturing Market Include** ### **South America Biosimilar Contract Manufacturing Market Industry Developments** Recent developments in the South America Biosimilar Contract Manufacturing Market indicate significant growth driven by increasing healthcare needs and regulatory support for biosimilars. Biocon has expanded its presence in Brazil, emphasizing partnerships to enhance local production capabilities. Sandoz has also made strides in this market, focusing on the accessibility of affordable biologics. Eli Lilly and Amgen continue to invest in Research and Development to bring innovative biosimilars to the region. In September 2023, Pfizer and Lonza announced a collaboration to boost biomanufacturing capacity in South America, reinforcing their commitment to local market growth. Additionally, Roche is enhancing its supply chain efficacy to meet growing demands. The market has experienced notable movements in valuations, with companies like Fresenius Kabi and Mylan also reporting positive growth trajectories. In 2022, the Brazilian government initiated funding for biosimilar projects, fostering an environment conducive to growth, while the regulatory landscape is increasingly favorable for new entrants. Recent partnerships and investments signal a robust outlook as these companies align their strategies to capture market opportunities in the region, propelling the South America Biosimilar Contract Manufacturing Market forward. ### **South America Biosimilar Contract Manufacturing Market Segmentation Insights** #### **Biosimilar Contract Manufacturing Market Product Outlook** #### **Biosimilar Contract Manufacturing Market Production Technology Outlook** #### **Biosimilar Contract Manufacturing Market Application Outlook** #### **Biosimilar Contract Manufacturing Market Regional Outlook** ## Market Drivers ### Growing Patient Population The expanding patient population in South America is another significant driver influencing the biosimilar contract-manufacturing market. With a population exceeding 420 million, the region faces increasing healthcare challenges, including chronic diseases that require biologic treatments. The prevalence of conditions such as diabetes and cancer is on the rise, necessitating the availability of effective and affordable treatment options. As a result, the demand for biosimilars is expected to surge, prompting contract manufacturers to scale their operations. The biosimilar contract-manufacturing market is thus positioned to play a crucial role in addressing these healthcare needs by providing accessible alternatives to traditional biologics. ### Increasing Healthcare Expenditure The rising healthcare expenditure in South America is a pivotal driver for the biosimilar contract-manufacturing market. Governments and private sectors are investing more in healthcare, aiming to improve access to affordable treatments. In 2025, healthcare spending in the region is projected to reach approximately $500 billion, reflecting a growth of around 8% annually. This increase in funding is likely to enhance the development and production of biosimilars, as healthcare providers seek cost-effective alternatives to expensive biologics. Consequently, the biosimilar contract-manufacturing market stands to benefit from this trend, as manufacturers align their capabilities to meet the growing demand for affordable therapies. ### Regulatory Support for Biosimilars Regulatory support for biosimilars in South America is a crucial driver for the contract-manufacturing market. Governments are increasingly recognizing the importance of biosimilars in improving healthcare access and reducing costs. Regulatory bodies are streamlining approval processes, which encourages manufacturers to invest in biosimilar production. For instance, Brazil's regulatory agency has implemented guidelines that facilitate the entry of biosimilars into the market, potentially increasing the number of approved products by 30% over the next few years. This supportive regulatory environment is likely to bolster the biosimilar contract-manufacturing market, as it creates a more favorable landscape for manufacturers to operate and innovate. ### Technological Innovations in Production Technological innovations in production processes are significantly impacting the biosimilar contract-manufacturing market. Advances in bioprocessing technologies, such as single-use systems and continuous manufacturing, are enhancing efficiency and reducing costs. In South America, manufacturers are increasingly adopting these technologies to improve their production capabilities. The implementation of such innovations can lead to a reduction in production time by up to 25%, allowing for quicker market entry of biosimilars. As a result, the biosimilar contract-manufacturing market is likely to experience growth driven by these technological advancements, enabling manufacturers to meet the rising demand for biosimilars more effectively. ### Strategic Partnerships and Collaborations Strategic partnerships and collaborations among pharmaceutical companies and contract manufacturers are emerging as a key driver in the biosimilar contract-manufacturing market. These alliances facilitate knowledge sharing, resource pooling, and technological advancements, which are essential for the efficient production of biosimilars. In South America, several companies are forming joint ventures to enhance their manufacturing capabilities and expand their product portfolios. Such collaborations not only reduce operational costs but also accelerate the time-to-market for new biosimilars. The biosimilar contract-manufacturing market is likely to witness increased activity in this area, as stakeholders recognize the benefits of working together to navigate the complexities of biosimilar development. ## Future Outlook The [Biosimilar Contract Manufacturing Market](https://www.marketresearchfuture.com/reports/biosimilar-contract-manufacturing-market-11903) is projected to experience a decline of -3.35% CAGR from 2025 to 2035, driven by regulatory challenges and market saturation. **New opportunities:** - Invest in advanced bioreactor technologies to enhance production efficiency. - Develop strategic partnerships with local biotech firms for market penetration. - Implement cost-reduction strategies through automation in manufacturing processes. By 2035, the market is expected to stabilize, albeit at a reduced scale. ## Segment Insights ### By Product: Recombinant Non-glycosylated Proteins (Largest) vs. Recombinant Glycosylated Proteins (Fastest-Growing) In the South America biosimilar contract-manufacturing market, recombinant non-glycosylated proteins hold the largest share due to their extensive applications across various therapeutic areas. This segment is well-established and accounts for a significant portion of the market, driven by consistent demand from pharmaceutical companies focusing on production efficiency and cost-effectiveness. On the other hand, recombinant glycosylated proteins are emerging as the fastest-growing segment, primarily influenced by advancements in biopharmaceutical technologies. The increasing prevalence of chronic diseases and the rising focus on personalized medicine are key drivers propelling this growth, indicating a shift towards more complex protein structures that offer higher efficacy in treatment solutions. Recombinant Non-glycosylated Proteins (Dominant) vs. Recombinant Glycosylated Proteins (Emerging) Recombinant non-glycosylated proteins are characterized by their simpler structure, making them easier and more cost-effective to produce. This dominant segment is typically utilized in a wide range of therapeutic applications, including hormones and enzymes. In contrast, recombinant glycosylated proteins, while being more complex and challenging to manufacture, are gaining traction due to their superior functional properties and effectiveness in treating diseases. As biomanufacturing techniques evolve, the emerging glycosylated segment is expected to capture a growing share of the market, appealing particularly to companies looking to innovate and differentiate their product offerings. ### By Production Technology: Mammalian (Largest) vs. Non-Mammalian (Fastest-Growing) In the Production Technology segment, the mammalian technology remains the dominant player, accounting for a significant share of the market. This preference is largely due to the ability of mammalian systems to produce complex biologics that closely mimic human proteins, which is crucial for the efficacy and safety of biosimilars. Non-mammalian systems, while currently holding a smaller share, are gaining traction as advances in technology make them more viable for certain applications. The growth trend for this segment is being driven by several factors, including increased investment in biomanufacturing and enhanced product pipelines for biosimilars. The demand for cost-effective production methods is pushing companies to explore non-mammalian options, which are anticipated to become more prominent as the technology matures. Additionally, regulatory support for non-mammalian systems could further bolster their growth in the coming years. Production Technology: Mammalian (Dominant) vs. Non-Mammalian (Emerging) Mammalian production technology is characterized by its ability to produce highly sophisticated biologics, making it the preferred choice for many biosimilar developers. This dominance stems from its extensive track record in the industry and the reliability in producing therapeutic proteins that meet stringent regulatory requirements. On the other hand, non-mammalian production technology, though considered emerging, is rapidly evolving. It presents advantages such as lower production costs and faster turnaround times. As innovations continue to enhance the capabilities of non-mammalian systems, these technologies are increasingly recognized for their potential to meet specific production needs, appealing to manufacturers looking for more flexibility and efficiency in their operations. ### By Application: Oncology (Largest) vs. Chronic & Autoimmune Disorders (Fastest-Growing) In the South America biosimilar contract-manufacturing market, the application segment is prominently led by Oncology, which holds the largest market share due to the rising incidence of cancer and the demand for affordable treatment options. Following Oncology, Blood Disorders and Growth Hormonal Deficiency also command significant shares, while Chronic & Autoimmune Disorders are rapidly gaining traction owing to increasing awareness and healthcare access. Growth trends in this segment are being driven by innovation in biosimilar development and a focus on expanding treatment options for chronic diseases. The growing. prevalence of conditions such as Rheumatoid Arthritis and autoimmune disorders, coupled with supportive regulatory frameworks, positions Chronic & Autoimmune Disorders as the fastest-growing segment, forecasted to shape the future landscape of contract manufacturing services for biosimilars. Oncology (Dominant) vs. Chronic & Autoimmune Disorders (Emerging) Oncology remains the dominant application in the contract-manufacturing sector, as it is pivotal in addressing the significant healthcare burden posed by cancer. Manufacturers are focusing on efficiency and quality in producing oncological biosimilars to meet the increasing demands of healthcare providers and patients. Conversely, Chronic & Autoimmune Disorders represent an emerging opportunity characterized by a growing patient base and a need for innovative treatment solutions. This segment is experiencing enhanced interest from contract manufacturers, encouraged by advancements in biotechnology and a favorable regulatory landscape. As more biosimilars become available for these conditions, the segment is expected to expand, reflecting a crucial shift in treatment paradigms that emphasize cost-effective healthcare solutions. ## Regional Market Share Analysis ### Brazil : Strong Market Growth and Demand Brazil holds a dominant position in the South American biosimilar contract-manufacturing market, with a market share of 43.5% valued at $180.0 million. Key growth drivers include increasing healthcare expenditure, a rising aging population, and government initiatives promoting biosimilars. Regulatory policies are becoming more favorable, with ANVISA streamlining approval processes, which enhances market accessibility. Additionally, Brazil's robust infrastructure supports industrial development, facilitating efficient manufacturing and distribution. ### Mexico : Growing Demand and Investment Opportunities Mexico accounts for 22.5% of the South American biosimilar contract-manufacturing market, valued at $90.0 million. The market is driven by increasing demand for affordable healthcare solutions and a growing biopharmaceutical sector. Government initiatives, such as the promotion of public-private partnerships, are fostering investment in biosimilar production. The regulatory environment is evolving, with COFEPRIS enhancing its guidelines to support biosimilar approvals, thus encouraging local manufacturing. ### Argentina : Strategic Growth in Biopharmaceuticals Argentina holds a 17.5% market share in the biosimilar contract-manufacturing sector, valued at $70.0 million. The growth is fueled by increasing healthcare demands and a focus on local production of biologics. Regulatory frameworks are being updated to facilitate biosimilar approvals, with ANMAT playing a crucial role. The country is witnessing a rise in biopharmaceutical companies, supported by government incentives aimed at boosting local manufacturing capabilities. ### Rest of South America : Untapped Markets and Growth Potential The Rest of South America represents a smaller segment of the biosimilar contract-manufacturing market, with a share of 11.5% valued at $46.43 million. Growth is driven by increasing healthcare access and the need for cost-effective treatments. Countries like Chile and Colombia are emerging as potential markets, with supportive regulatory frameworks being established. The competitive landscape is evolving, with both local and international players seeking to enter these markets, driven by sector-specific applications in oncology and autoimmune diseases. ## Competitive Benchmarking The biosimilar contract-manufacturing market is currently characterized by a dynamic competitive landscape, driven by increasing demand for cost-effective biologics and the need for localized production capabilities. Key players such as Samsung Biologics (KR), Lonza Group (CH), and Boehringer Ingelheim (DE) are strategically positioned to leverage their extensive manufacturing networks and technological expertise. Samsung Biologics (KR) focuses on expanding its production capacity through advanced biomanufacturing technologies, while Lonza Group (CH) emphasizes partnerships with biotech firms to enhance its service offerings. Boehringer Ingelheim (DE) is actively pursuing innovation in bioprocessing, which collectively shapes a competitive environment that is increasingly reliant on technological advancements and strategic collaborations.In terms of business tactics, companies are localizing manufacturing to reduce supply chain vulnerabilities and optimize operational efficiencies. The market appears moderately fragmented, with several players vying for market share, yet the influence of major companies remains substantial. This competitive structure encourages innovation and responsiveness to market demands, as firms seek to differentiate themselves through quality and reliability. In October Samsung Biologics (KR) announced the opening of a new state-of-the-art facility in Brazil, aimed at enhancing its production capabilities for biosimilars. This strategic move is likely to bolster its presence in the South American market, allowing for quicker response times to local demand and potentially reducing logistics costs. The facility is expected to utilize cutting-edge biomanufacturing technologies, aligning with the company's commitment to innovation. In September Lonza Group (CH) entered into a partnership with a prominent South American biotech firm to co-develop a biosimilar product. This collaboration is indicative of Lonza's strategy to expand its portfolio and strengthen its foothold in the region. By leveraging local expertise and resources, Lonza may enhance its competitive edge while addressing specific market needs more effectively. In August Boehringer Ingelheim (DE) launched a new initiative focused on sustainability in its manufacturing processes, aiming to reduce carbon emissions by 30% by 2030. This initiative not only reflects a growing trend towards environmentally responsible practices but also positions Boehringer as a leader in sustainable biomanufacturing. Such efforts may resonate well with stakeholders increasingly concerned about the environmental impact of pharmaceutical production. As of November the competitive trends in the biosimilar contract-manufacturing market are increasingly defined by digitalization, sustainability, and the integration of AI technologies. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in navigating complex market dynamics. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability, suggesting a transformative shift in how companies position themselves in the market. ## Recent News & Developments Recent developments in the South America Biosimilar Contract Manufacturing Market indicate significant growth driven by increasing healthcare needs and regulatory support for biosimilars. Biocon has expanded its presence in Brazil, emphasizing partnerships to enhance local production capabilities. Sandoz has also made strides in this market, focusing on the accessibility of affordable biologics. Eli Lilly and Amgen continue to invest in Research and Development to bring innovative biosimilars to the region. In September 2023, Pfizer and Lonza announced a collaboration to boost biomanufacturing capacity in South America, reinforcing their commitment to local market growth. Additionally, Roche is enhancing its supply chain efficacy to meet growing demands. The market has experienced notable movements in valuations, with companies like Fresenius Kabi and Mylan also reporting positive growth trajectories. In 2022, the Brazilian government initiated funding for biosimilar projects, fostering an environment conducive to growth, while the regulatory landscape is increasingly favorable for new entrants. Recent partnerships and investments signal a robust outlook as these companies align their strategies to capture market opportunities in the region, propelling the South America Biosimilar Contract Manufacturing Market forward. ## Report Scope | MARKET SIZE 2024 | 386.43(USD Million) | | --- | --- | | MARKET SIZE 2025 | 373.48(USD Million) | | MARKET SIZE 2035 | 265.61(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | -3.35% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Samsung Biologics (KR), Lonza Group (CH), Boehringer Ingelheim (DE), Fujifilm Diosynth Biotechnologies (JP), Catalent (US), Wuxi Biologics (CN), Rentschler Biopharma (DE), KBI Biopharma (US), Amgen (US) | | Segments Covered | Product, Production Technology, Application | | Key Market Opportunities | Growing demand for cost-effective biosimilars drives expansion in the biosimilar contract-manufacturing market. | | Key Market Dynamics | Rising demand for cost-effective biosimilars drives competitive contract-manufacturing partnerships in South America. | | Countries Covered | Brazil, Mexico, Argentina, Rest of South America | ## Frequently Asked Questions **Q: What was the market valuation of the biosimilar contract-manufacturing market in 2024?** A: The market valuation was $386.43 Million in 2024. **Q: What is the projected market valuation for 2035?** A: The projected market valuation for 2035 is $265.61 Million. **Q: What is the expected CAGR for the biosimilar contract-manufacturing market during the forecast period 2025 - 2035?** A: The expected CAGR during the forecast period 2025 - 2035 is -3.35%. **Q: Which companies are considered key players in the biosimilar contract-manufacturing market?** A: Key players include Samsung Biologics, Lonza Group, Boehringer Ingelheim, and Fujifilm Diosynth Biotechnologies. **Q: What were the valuations for recombinant non-glycosylated proteins in 2024?** A: The valuation for recombinant non-glycosylated proteins was $200.0 Million in 2024. **Q: How did the valuation for recombinant glycosylated proteins compare in 2024?** A: The valuation for recombinant glycosylated proteins was $186.43 Million in 2024. **Q: What was the market size for mammalian production technology in 2024?** A: The market size for mammalian production technology was $250.0 Million in 2024. **Q: What is the valuation for oncology applications in the biosimilar contract-manufacturing market?** A: The valuation for oncology applications was $80.0 Million in 2024. **Q: What were the valuations for chronic and autoimmune disorders in 2024?** A: The valuations for chronic and autoimmune disorders was $70.0 Million in 2024. **Q: What is the projected trend for the biosimilar contract-manufacturing market in South America?** A: The market appears to be declining, with a projected valuation decrease to $265.61 Million by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-america-biosimilar-contract-manufacturing-market-51872*